Ann Lab Med.  2018 May;38(3):274-276. 10.3343/alm.2018.38.3.274.

Circulating Microparticles and Coagulation Profiles in Patients with Advanced Stage Solid Tumors

• Sun DS
• Lee HK
• Kim Y
• Lee JH
• Won HS
• Ko YH
• Kim H

• KMID: 2403464
• DOI: http://doi.org/10.3343/alm.2018.38.3.274

Abstract

No abstract available.

MeSH Terms

Humans

Figure

• 

  Fig. 1 Scatter diagrams and regression lines for platelet-derived microparticle (PMP) counts and endothelial cell-derived microparticle (EMP) with levels of D-dimers and fibrinogen degradation products (FDP). PMP and EMP counts showed moderate correlations with D-dimer and FDP levels, respectively.

Reference

1. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166:458–464. PMID: 16505267.

2. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343:1846–1850. PMID: 11117976.

3. Thaler J, Ay C, Weinstabl H, Dunkler D, Simanek R, Vormittag R, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol. 2011; 90:447–453. PMID: 20981426.

4. Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost. 2003; 1:2561–2568. PMID: 14738565.

5. Zhang X, McGeoch SC, Johnstone AM, Holtrop G, Sneddon AA, MacRury SM, et al. Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014; 37:455–463. PMID: 24097206.

6. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39:175–191. PMID: 17695343.

7. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009; 7:1421–1423. PMID: 19500241.

8. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010; 125:511–512. PMID: 19854471.

9. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002; 88:745–749. PMID: 12428088.

10. Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013; 43:277–285. PMID: 23398637.